

# Notice of Interim Results

---

[VIEW ALL PRESS RELEASES](#)

Company Name: ACACIA PHARMA Market: Euronext ISIN: GB00BYWF9Y76

Symbol: ACPH

RELEASE 31 UG 2018 08:00 CET

**Cambridge, UK and Indianapolis, US - 31 August 2018:** Acacia Pharma Group plc ("Acacia Pharma", the "Company" or the "Group"), (EURONEXT: ACPH), today announces that the Company will issue its interim results for the six-month period ended 30 June 2018 on Friday 7 September 2018.

A conference call will take place on the same date at 14:00 CEST. Dr. Julian Gilbert, CEO and Christine Soden, CFO will present the financial and operational results followed by a Q&A session.

The dial-in numbers for the conference call are:

Belgium: 0800 746 68

Netherlands: 0800 022 9132

UK Toll Free: 0808 109 0700

USA Toll Free: +1 866 966 5335

Standard International Access: +44 (0) 20 3003 2666

The call Password is Acacia.

ACACIA PHARMA GROUP PLC

DR. JULIAN GILBERT, CEO

**Ends**

**Contacts**

**Acacia Pharma Group plc**

Julian Gilbert, CEO

Christine Soden, CFO

+44 1223 919760

[IR@acaciapharma.com](mailto:IR@acaciapharma.com)

**Citigate Dewe Rogerson (Financial PR)**

Mark Swallow, Shabnam Bashir, David Dible

+44 20 7638 9571

[acaciapharma@citigatedewerogerson.com](mailto:acaciapharma@citigatedewerogerson.com)

**About Acacia Pharma**

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.

The Group's lead project, BARHEMSYS(TM) (amisulpride injection) for post-operative nausea & vomiting (PONV), has successfully completed Phase 3 clinical studies and an NDA is under review by the US FDA for marketing approval. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. [www.acaciapharma.com](http://www.acaciapharma.com)

Source: Acacia Pharma Group plc

Provider: Thomson Reuters ONE